Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history
It is no secret that GLP-1 agonist medications like semaglutide Ozempic, Wegovy have demonstrated both effectiveness and popularity for treating obesity, he told us
CAROLYN BRAMANTE: Yeah, so exactly, that's one of the concerns, especially in older adults, is that weight loss usually goes with losing muscle and fat-- fat tissue
doi: 10.1177/20420188231222367 11 MadsenMSAHolmJBPallejAWismannPFabriciusKRigboltKet al
And a 2010 study in the journal Nutrition Research found that when mildly overweight, healthy women took saffron extract another Lemme ingredient they snacked less, which could help with some weight loss
Postgrad Med
